Stimart Tryn 4
4 · AbCellera Biologics Inc. · Filed Jun 9, 2021
Insider Transaction Report
Form 4
Stimart Tryn
Chief Legal Officer
Transactions
- Exercise/Conversion
Share Option (right to buy)
2021-06-07−750,000→ 1,250,000 totalExercise: $0.32Exp: 2029-08-22→ Common Shares (750,000 underlying) - Exercise/Conversion
Share Option (right to buy)
2021-06-07−250,000→ 600,000 totalExercise: $2.30Exp: 2030-10-29→ Common Shares (250,000 underlying) - Exercise/Conversion
Common Shares
2021-06-07$2.30/sh+250,000$575,000→ 1,000,250 total - Exercise/Conversion
Common Shares
2021-06-07$0.32/sh+750,000$240,000→ 750,250 total
Holdings
- 250(indirect: By Spouse)
Common Shares
Footnotes (3)
- [F1]Previously reported on Form 3 filed on December 11, 2020. The vesting schedule was amended as follow: 25% of the shares subject to such option vest and become exercisable on August 22, 2020; 6.25% of the shares subject to such option vest and become exercisable on November 22, 2020 and February 22, 2021; 4.70% of the shares subject to such option vest and become exercisable on on July 1, 2022; 8.9% of the shares subject to such option vest and become exercisable on October 1, 2022; 7.4% of the shares subject to such option vest and become exercisable on January 1, 2023; 10.40% of the shares subject to such option vest and become exercisable on April 1, 2023; 8.90% of the shares subject to such option vest and become exercisable on July 1, 2023 and October 1, 2023; 2.70% of the shares subject to such option vest and become exercisable on January 1, 2024;
- [F2](Continued from footnote 1) and 2.65% of the shares subject to such option vest and become exercisable on April 1, 2024, July 1, 2024, October 1, 2024 and January 1, 2025.
- [F3]Previously reported on Form 3 filed on December 11, 2020 and Form 4 filed on December 17, 2020. The vesting schedule was amended such that all of the shares subject to such option were vested as of March 24, 2021.